Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 07:00 ET | Source: Anteris Technologies Global Corp.

FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and...
October 20, 2025 09:20 ET | Source: SNS Insider pvt ltd

Interventional Cardiology Devices Market to Hit USD 37.29 Billion by 2032, Driven by Rising Cardiovascular Disease Burden and Adoption of Minimally Invasive Therapies – SNS Insider

Austin, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Interventional Cardiology Devices Market Size & Growth Analysis According to SNS Insider, the global Interventional Cardiology Devices Market was...
May 13, 2025 17:45 ET | Source: Anteris Technologies Global Corp.

Anteris Announces Results for the First Quarter of 2025

Anteris Announces Results for the First Quarter of 2025
March 31, 2025 07:15 ET | Source: Anteris Technologies Global Corp.

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Anteris Technologies reaches clinical milestone: 100 patients treated with DurAVR® Transcatheter Heart Valve (THV)
March 21, 2025 07:30 ET | Source: Anteris Technologies Global Corp.

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

MINNEAPOLIS and BRISBANE, Australia, March 21, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company...
March 12, 2025 20:33 ET | Source: Anteris Technologies Global Corp.

Anteris Reports 2024 Financial Results and Provides Corporate Update

Anteris Technologies Global Corp. Reports 2024 Financial Results and Provides Corporate Update
December 06, 2024 08:21 ET | Source: Bleichmar Fonti & Auld

EW COURT NOTICE: Edwards Lifesciences Investors with Losses are Notified of December 13 Court Deadline in Securities Fraud Class Action – Contact BFA Law (NYSE:EW)

Edwards Lifesciences Corporation investors that lost money on their investment are encouraged to contact BFA Law before December 13, 2024 legal deadline.
October 23, 2024 17:21 ET | Source: DiCello Levitt LLP

INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Edwards Lifesciences Corporation (NYSE: EW); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel

SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Edwards Life Sciences Corporation. (NYSE:...
August 31, 2023 09:56 ET | Source: The Insight Partners

Aortic Valve Replacement Devices Market worth $18.07 Billion by 2030 - Exclusive Report by The Insight Partners

Pune, India, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Aortic valve repair and aortic valve replacement are methods that treat diseases affecting the aortic valve. The aortic valve is one of four valves...
March 01, 2023 09:30 ET | Source: Persistence Market Research

Transcatheter Heart Valve Replacement Repair Market Size Will Attain US$ 25.5 Billion by 2033 at a CAGR of 13.0% | Persistence Market Research

New York, March 01, 2023 (GLOBE NEWSWIRE) -- The global Transcatheter Heart Valve Replacement Repair Market is currently valued at around US$ 7.5 Billion in 2023. Sales of the market are set to...